The GP 3 protein of the IAF-Klop strain of porcine reproductive and respiratory syndrome virus (PRRSV) was expressed in 293 cells by a recombinant human type 5 adenovirus carrying the open reading frame 3 gene. The protein exhibited a molecular mass of 42 kDa and comigrated with GP 3 expressed in PRRSV-infected MARC-145 cells. Removal of N-linked glycans from GP 3 resulted in a 27-kDa protein (P3), confirming its highly glycosylated nature. Pulse-chase experiments carried out either in the context of PRRSV infection or upon individual expression of GP 3 in 293 cells showed that the protein remains completely endo-␤-N-acetylglucosaminidase H-sensitive even after 4 h of synthesis. Thus, the transport of GP 3 was restricted to the premedial Golgi compartment, presumably the endoplasmic reticulum (ER). However, a minor fraction of GP 3 was found to be secreted in the culture medium as a soluble membrane-free form. This released protein (sGP 3 ) was readily identified upon individual expression of GP 3 in 293 cells as well as in the context of PRRSV infection, albeit at lower levels. The sGP 3 migrated as a smear and displayed a molecular mass ranging from 43 to 53 kDa. The unglycosylated form of sGP 3 comigrated with its intracellular deglycosylated counterpart, suggesting that the release from the cell of a subset of GP 3 did not result from cleavage of a putative membrane-anchor sequence. Strikingly, unlike GP 3 , the sGP 3 acquired Golgi-specific modifications of its carbohydrate side chains and folded into a disulfide-linked homodimer. Brefeldin A treatment completely abolished the release of sGP 3 , suggesting that the ER-to-Golgi compartment is an obligatory step in cellular secretion of sGP 3 . In contrast, 10 mM monensin did not prevent sGP 3 release but inhibited the terminal glycosylation that confers on the protein its diffuse pattern. Since GP 3 was found to be nonstructural in the case of the North American strain, secretion of a minor fraction of GP 3 might be an explanation for its high degree of immunogenicity in infected pigs. Furthermore, this secreted protein might be relevant as a model for further studies on the cellular subcompartments involved in the sorting of proteins to the extracellular milieu.
Porcine reproductive and respiratory syndrome virus (PRRSV) belongs to the recently recognized Arteriviridae family within the genus Arterivirus, order Nidovirales, along with equine arteritis virus (EAV), lactate dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (5, 11) . Mature PRRS virions are enveloped and contain an icosahedral capsid which encloses a linear plus-strand RNA genome of approximately 15 kb (41) . The latter contains eight open reading frames (ORFs), designated (5Ј to 3Ј) ORF1a, ORF1b, and ORF2 to ORF7. Aside from the genome-length mRNA, expression of the viral genome involves the synthesis of a 3Ј coterminal nested set of six subgenomic mRNAs (8) . The available evidence indicates that only the 5Ј-most ORF is translated from each one of these subgenomic mRNAs. According to sequence data, ORF1a and ORF1b are expected to produce functional products associated with virus replication (14) .
At least five PRRSV structural proteins, designated GP 2 , GP 4 , GP 5 (or E), M, and N, have been identified and found to be encoded by ORF2 and ORF4 to ORF7, respectively (38, 40, 42) . While N (15 kDa) is the major protein of the capsid, GP 2 (29 to 30 kDa), GP 4 (28 to 31 kDa), GP 5 (24 to 26 kDa), and M (18 to 19 kDa) are membrane associated. The latter two are present as disulfide-linked heterodimers and are the major components of the virus envelope (37) . Among these structural proteins, only GP 2 , GP 4 , and GP 5 are modified by N-linked glycans (37, 40, 42) . With the exception of GP 4 , the other structural proteins (GP 2 , GP 5 , M, and N) have also been identified for EAV (12, 13) and LDV (18) . Moreover, it has been shown that the envelope of Lelystad virus (LV), the European prototype of PRRSV, accomodates a fifth minor protein, of 45 to 50 kDa, encoded by ORF3 (42, 54) . This finding was unexpected, since previous reports indicate that the ORF3-encoded protein is incorporated neither into LDV particles (19) nor into PRRS virions (27, 60) . In the case of LDV, in vitro studies have shown that the ORF3 product is weakly associated with the membrane and tends to be soluble (19) . Finally, by using a monospecific antiserum raised against Escherichia coli-expressed ORF3 product, we have recently confirmed the nonstructural nature of the GP 3 of a reference Quebec strain of PRRSV (22) .
The role of the ORF3 product in the life cycle of arteriviruses remains unknown. Therefore, full characterization of this viral protein is required. Apart from its nonstructural nature, recent reports indicate that the ORF3 product is highly anti-genic (19, 22, 27) , and in one experiment, this protein was shown to provide protection for piglets against PRRSV infection in the absence of a noticeable neutralizing-antibody response (49) . These features have prompted us to undertake a detailed study aimed at characterizing this protein. In the present study, the intracellular processing of PRRSV ORF3 product was analyzed either in the context of PRRSV infection or upon individual expression of the protein in mammalian cells. Data demonstrated that a minor fraction of GP 3 is secreted into cell culture fluids as a soluble protein (sGP 3 ), whereas the bulk of the protein remains associated with the endoplasmic reticulum (ER). Unlike its intracellular counterpart, sGP 3 appears as a smear due to extensive and complex Golgi-specific modifications of its carbohydrate side chains. By using protein transport inhibitors, the release of sGP 3 from the cell has been found to occur by transit through the secretory pathway. 6 -cpm aliquots were incubated overnight at 4°C with 5 l of normal rabbit sera or specific antisera. Immune complexes were then collected by addition of protein ASepharose CL4B (Pharmacia) and analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) as previously described (37) . For immunoprecipitation of extracellular proteins, culture fluids of radiolabelled cells were clarified by a centrifugation at 3,000 ϫ g for 15 min at 4°C. Thereafter, protease inhibitors and lysis buffer were added, and the samples were processed for SDS-PAGE, as described above.
In vivo inhibition of N-linked glycosylation and protein transport. For Nlinked glycosylation and protein transport inhibition experiments, infected 293 cells were pretreated for 1 h either with 5 g of tunicamycin (TUN) (Boehringer Mannheim)/ml, 5 g of brefeldin A (BFA) (Sigma)/ml, or 10 M monensin (MNS) (Sigma) in methionine-deprived DMEM prior to labelling with [
35 S]methionine in the presence of the aforementioned drugs. When labelling was carried out overnight in the presence of BFA, the latter was added freshly every 4 h, since it has been reported that the activity of BFA gradually decreases during incubation (7) .
Carbohydrate analysis by glycosidase digestion. Immunoprecipitated proteins bound to protein A-Sepharose CL4B beads were suspended in 200 l of either endo-␤-N-acetylglucosaminidase H (Endo H) buffer (50 mM sodium acetate [pH 6], 2 mM PMSF, 1 g of aprotinin/ml), endoglycosidase F-N-glycosidase F (Glyco F) buffer (50 mM sodium acetate [pH 6 .0], 10 mM EDTA, 1% [vol/vol] ␤-mercaptoethanol, 2 mM PMSF, 1 g of aprotinin/ml), endo-␤-galactosidase (Endo ␤) buffer (50 mM sodium acetate [pH 5.8], 200 g of bovine serum albumin/ml, 2 mM PMSF, 1 g of aprotinin/ml), or O-glycosidase buffer (Trismaleate, [pH 6.8], 2 mM PMSF, 1 g of aprotinin/ml) and treated overnight at 37°C with 4, 200, 3, and 4 mU of enzyme, respectively. Removal of sialic acid was performed by incubating immune complexes for 2 h at 37°C in a buffer containing 0.5% NP-40, 10 mM Tris (pH 7.4), 0.5 M NaCl, and 200 mU of neuraminidase per ml. All glycosidases were purchased from Boehringer Mannheim, Laval, Quebec, Canada. After the incubation period, immunoprecipitates were washed in 20 mM Tris-HCl, (pH 7.6), and analyzed by SDS-PAGE. Control samples were incubated under identical conditions but in the absence of enzyme. Alternatively, glycosidase treatments were performed on denatured proteins. Immunoprecipitated proteins were dissociated from the protein A-Sepharose CL4B beads by boiling the samples for 5 min in 20 l of sample loading buffer containing 1% SDS, 10% glycerol, 5% ␤-mercaptoethanol, and 62 mM Tris (pH 6.8). The denatured proteins were suspended in 200 l of the glycosidase buffer supplemented with 1% N-octylglucoside and treated with the corresponding glycosidase, as described above.
Treatment of extracellular GP 3 protein with trypsin. The culture fluid of [ 35 S]methionine-labelled 293 cells expressing GP 3 was clarified at 15,000 ϫ g for 10 min, and the resulting supernatant was directly divided into five equal portions and processed as follows. Portion 1 was left untreated, portion 2 was incubated with trypsin (11,500 U/mg) at a final concentration of 300 g/ml, portion 3 received trypsin plus 1% NP-40, portion 4 received trypsin plus soybean trypsin inhibitor (final concentration of 500 g/ml), and portion 5 received only soybean trypsin inhibitor. All samples were incubated at room temperature for 30 min. Thereafter, trypsin inhibitor, PMSF, and aprotinin were added to all samples, which were then mixed with 5ϫ lysis buffer and processed for immunoprecipitation as described above.
RESULTS

Expression of GP 3 in 293 cells infected with a recombinant
Ad carrying the ORF3. To firmly establish the nature of the PRRSV ORF3-encoded protein, a monospecific antiserum raised against the E. coli-expressed ORF3 product (␣3) was developed as previously described (22, 37) . From lysates of PRRSV-infected MARC-145 cells, ␣3 efficiently immunoprecipitated the GP 3 protein, which migrated at the expected molecular size of 42 kDa (Fig. 1A, lane 1) . To further characterize this protein, the cDNA sequence encoding the complete PRRSV GP 3 was inserted into the E1A region of human type 5 Ad under the control of the CMV immediate-early promoter and enhancer, as described in Materials and Methods. Ad-CMV5/ORF3, a recombinant Ad carrying the PRRSV ORF3 gene, was identified by PCR, and the expression of GP 3 in 293 cells was monitored by indirect immunofluorescence. Human 293 cells were then infected with plaque-purified AdCMV5/ ORF3 (MOI of 30 TCID 50 /cell) and radiolabelled at 17 to 17.5 h postinfection (p.i.). Detergent extracts of infected or mock-infected cells were mixed with ␣3 antiserum and immune complexes were precipitated by protein A-Sepharose. A 42-kDa protein having a migration profile similar to that of the GP 3 synthesized in PRRSV-infected cells was efficiently precipitated by ␣3 antiserum from AdCMV5/ORF3-infected 293 cells ( Fig. 1A ; compare lanes 1 and 3) but not by that from the mock-infected cells ( Fig. 1A; compare lanes 3 and 4) , confirming the identity of the PRRSV ORF3 product. It is noteworthy that a protein of approximately 31 kDa was substantially coprecipitated with GP 3 . This protein has been recently identified as the product of ORF4, referred to as GP 4 (21) . Coprecipitation of the latter protein still occurred when immunoprecipitates were extensively washed with lysis buffer containing SDS, and the amount of GP 4 brought down by ␣3 antiserum did not increase when salts and SDS were omitted from the lysis buffer (data not shown). As previously reported by others, in studies with recombinant Ads expressing genes from other heterologous viruses (25, 39, 59) , the 110-kDa hexon protein of Ad type 5 was consistently coprecipitated from lysates of AdCMV5/ORF3-infected cells (Fig. 1A, lane  3) .
Glycosylation of GP 3 synthesized in PRRSV-infected MARC-145 cells. To analyze the nature of the carbohydrate content of GP 3 , ␣3 immunoprecipitates from PRRSV-infected cells were subjected to treatment with Glyco F or Endo H. Under the conditions used, GP 3 was sensitive to Glyco F, an enzyme mixture which hydrolyzes N-glycans of the high-mannose and complex type. The resulting nonglycosylated product (P3) displayed a molecular mass of approximately 27 kDa (Fig.  1B, lane F) , which was consistent with that predicted from the amino acid sequence of the ORF3 product after removal of the predicted N-terminal signal sequence (38, 58) . However, it remains to be determined whether the cleavage of the putative N-terminal signal sequence has occurred. A similar electrophoretic profile was obtained after treatment with Endo H (Fig. 1B, lane H) , an enzyme which cleaves high-mannose and hybrid oligosaccharides which are added in the ER compartment but not complex-type oligosaccharides which occur in the Golgi complex. No resistance, not even partial, could be observed with Endo H. Taking into account that cells were labelled for a period of 30 min, this indicates that in PRRSVinfected cells, GP 3 protein carbohydrates might be processed slowly to the complex type, a finding that has been previously reported for PRRSV GP 5 (37) as well as for GP 2 and GP 4 (40, 43) .
Intracellular stability and transport of GP 3 protein expressed in the context of PRRSV infection. Pulse-chase experiments were performed to examine in greater detail the processing of the GP 3 of the IAF-Klop strain of PRRSV. At 24 h p.i., PRRSV-infected MARC-145 cells were pulse-labelled with [ 35 S]methionine for 15 min (time zero) and processing of intracellular GP 3 was monitored during a chase period that varied from 15 to 240 min. Cell lysates were immunoprecipitated with ␣3 antiserum and subjected or not to treatment with either Glyco F or Endo H. As shown in Fig. 2A , GP 3 was readily detected within the pulse interval and migrated at the expected size. A gradual decrease in the mobility of the protein became apparent after a 2-h chase period, which was most 35 S]methionine for 15 min and chased in the presence of 5 mM nonradioactive methionine for the indicated periods. Cell lysates were immunoprecipitated with ␣3 antiserum and were then subjected to treatment with Glyco F or Endo H or were left untreated. Numbers on the right indicate the positions and sizes of marker proteins. The arrows show the two protein bands resulting from incomplete deglycosylation. Since they were also generated by Glyco F digestion, they must not be considered partially resistant to Endo H. likely due to the sequential removal of glycan moieties, as the mobility of the Glyco F-treated products remained unchanged during the entire chase. Also during the chase period, a marked decrease in the GP 3 amount occurred, presumably as a result of proteolysis. It is worth noting that in comparison with the three PRRSV major structural proteins (N, M, and GP 5 ), the breakdown of the GP 3 protein was much more considerable (data not shown). As mentioned above, GP 4 was consistently coprecipitated with GP 3 .
Strikingly, neither complete nor partial resistance to Endo H was observed during the pulse and the whole chase period (Fig.  2B) , suggesting that during PRRSV infection, the transport of GP 3 was restricted to the premedial Golgi compartment. Two minor bands (estimated M r s, 29 and 32 kDa) migrating slightly slower than the nonglycosylated GP 3 were observed after Endo H treatment (Fig. 2) . The possibility that these two additional precipitated bands correspond to cellular proteins recognized by the ␣3 antiserum was ruled out since they were not recovered from lysates of mock-infected cells. Since they were also generated upon Glyco F treatment, they were instead considered the results of incomplete deglycosylation. In the case of LV, the reference European PRRSV strain, anti-GP 3 monoclonal antibodies also immunoprecipitated at least four proteins with apparent molecular masses ranging from 28 to 44 kDa from Sf21 cells infected with baculovirus-ORF3 recombinants (54) . It was demonstrated that these protein bands correspond to the GP 3 that was N-glycosylated at different degrees (54) .
Processing of GP 3 individually expressed in 293 cells by a recombinant Ad and identification of an extracellular form.
The results described above indicate that GP 3 transport might be restricted to the premedial Golgi compartment, most probably in the ER, as the carbohydrate moieties of the protein remain Endo H sensitive even 4 h after synthesis. Since GP 3 was not found to be packaged into the IAF-Klop virus particle (22) , the possibility that GP 3 might be retained in that compartment (presumably through its interaction with other viral proteins) was investigated. The finding that GP 4 coprecipitates with GP 3 has reinforced such an assumption. A pulse-chase experiment was therefore conducted on 293 cells expressing GP 3 following their infection by the recombinant AdCMV5/ ORF3 virus. As shown in Fig. 3A , the GP 3 was efficiently expressed at levels consistently higher than that observed with PRRSV-infected MARC-145 cells. This is due to the higher MOI used with the recombinant Ad that could not be attained with the IAF-Klop strain of PRRSV, as well as to the optimized expression cassette that drives the synthesis of GP 3 from the recombinant Ad (39) . As in the case of PRRSV-infected MARC-145 cells, no resistance to Endo H could be detected at any time following GP 3 synthesis when the protein was individually expressed. The Endo H profile was identical to that obtained with Glyco F treatment. Thus, the processing of GP 3 expressed in the absence of any other viral product appeared similar to that observed in the context of PRRSV infection. Consequently, the ability of GP 3 to restrict its own transport to the premedial Golgi compartment appears to be an intrinsic property. Strikingly, when the supernatant of AdCMV5/ ORF3-infected 293 cells was analyzed by radioimmunoprecipitation with ␣3 antiserum, a protein band which migrated as a smear of approximately 43 to 53 kDa became apparent after a 1 h chase period and could be readily observed after 2 h of chase (Fig. 3B) . Since no other proteins were brought down in the ␣3 immunoprecipitates from the supernatant of AdCMV5/ ORF3-infected 293 cells, we hypothesized that this protein band, although having a different migration pattern than GP 3 , may represent a fraction of GP 3 (sGP 3 ) that was efficiently transported and has undergone other modifications leading to its secretion in the culture medium. Comparison of the intensities of the protein bands obtained from the supernatant fluids or lysates of Ad-infected cells indicated that approximately 20% of the GP 3 was secreted from the cells. The fact that sGP 3 occurred only in the culture medium of 293 cells expressing GP 3 and was completely absent from that of cells infected with the nonrecombinant parental Ad (Fig. 4A ) also strongly suggested that sGP 3 was indeed another form of GP 3 . This assumption was definitely confirmed by demonstrating that in the presence of TUN, the nonglycosylated product of this released form comigrated with P3, the nonglycosylated cell-associated form of GP 3 (Fig. 4B) . Finally, the finding that sGP 3 , displayed a different mobility pattern than GP 3 (Fig. 3B ) ruled out the possibility that it may have resulted from Ad-induced cell lysis and indicated that it was an active secreting process instead. Indeed, at the time when the pulse-chase experiment was performed (16 to 17 h p.i.), trypan blue staining of the Ad-infected cell monolayers revealed not more than 1 to 2% cell death, a level which was similar to that obtained with mock-infected cells (data not shown). sGP 3 is also generated in the context of PRRSV infection. During our preliminary experiments using ␣3 antiserum, a very faint diffuse band was constantly precipitated from the whole culture medium of PRRSV-infected MARC-145 cells (data not shown). In order to rule out the possibility that the latter band corresponds to a cellular contaminant that nonspecifically reacts with ␣3 antiserum rather than sGP 3 ]methionine for an additional 12 h. At that time, cytopathic effects and cell death were observed in less than 1 to 2% of the cells. The whole medium was centrifuged for 2 h at 100,000 ϫ g to pellet the virus and the supernatant was subjected to immunoprecipitation with ␣3 antiserum. As a negative control, a mock-infected culture of MARC-145 cells was similarly processed. As a positive control, 293 cells (3 ϫ 10 7 cells) were infected with AdCMV5/ORF3 virus (MOI of 20 to 30) and labelled as described above. A protein migrating as a diffuse band, with the same mobility as sGP 3 precipitated from the supernatant fluid of AdCMV5/ORF3-infected 293 cells, could be recovered in smaller amounts from the supernatant fluid of PRRSV-infected but not from that of mock-infected MARC-145 cells (Fig. 5) . A contaminant cellular protein of Ͻ30 kDa occasionally coprecipitated from the supernatant fluid of PRRSV-infected cultures. Since the latter could not be recovered from the supernatant fluid of AdCMV5/ORF3-infected cultures, it was not considered to represent the nonglycosylated form of GP 3 . Therefore, data showed that during PRRSV infection of MARC-145 cells, a fraction of GP 3 (about 10 to 20% of the amount of GP3 immunoprecipitated from PRRSV-infected cell lysates) was able to reach the extracellular compartment in a fashion which seems to be similar to that which occurs during individual expression of the protein. By radioimmunoprecipitation, neither GP 3 nor its released form, sGP 3 , could be identified in the viral pellet (even though highly concentrated virus stocks were used [22] ), which was in agreement with GP 3 being released in the culture medium as a non-virion-associated form. sGP 3 is released from the cell as a membrane-free form. The membrane topography of sGP 3 was investigated by assessing either its sensitivity to a dose of 350 U of trypsin/ml or its ability to be pelleted in association with membranes of microorganelles or small cytoplasmic vesicles. The results obtained are consistent with sGP 3 being released as a membrane-free form (Fig. 6) . Although we could not demonstrate that trypsinprotected fragments of Ͻ6 kDa were generated, it appeared that the major part of the protein was not protected by a lipid bilayer if the enzymatic digestion was done in either the presence or absence of the detergent NP-40 (Fig. 6A) . However, the protein was completely protected from digestion with trypsin in the presence of soybean trypsin inhibitor. Furthermore, when the clarified culture medium of AdCMV5/ORF3-infected 293 cells was subjected to a centrifugation of 1 to 2 h at 200,000 ϫ g, which is sufficient to pellet very small cytoplasmic vesicles (6) , no sGP 3 could be recovered in the pellet fraction with or without prior treatment with 1% Triton X-100 (Fig.  6B) . Taken together, the above results indicated that the released form of GP 3 is soluble.
The carbohydrate side chains of sGP 3 acquire Golgi-specific modifications. The fact that sGP 3 exhibited a smear pattern with a molecular mass greater than that of the intracellular GP 3 suggested that this soluble form may have been subjected to further modifications of its carbohydrate side chains. To determine whether the shift in mobility and the smear pattern of sGP 3 were indeed the results of complex-type glycosylation, ␣3 immunoprecipitates from the supernatant of AdCMV5/ ORF3-infected 293 cells were subjected to several glycosidases that cleave carbohydrates of a different nature. The first indication of a complex-type glycosylation of sGP 3 (10 7 ) infected with the nonrecombinant parental adenovirus (Ad5CMVlacZ) or infected with the recombinant adenovirus expressing GP 3 (AdCMV5/ORF3) were labelled for 1 h and then chased for 6 h. The culture medium was clarified at 3,000 ϫ g, and 5ϫ lysis buffer was added prior to radioimmunoprecipitation with ␣3 antiserum. The immunoprecipitates were then analyzed by SDS-12% PAGE. (B) 293 cells infected with AdCMV5/ORF3 were starved in DMEM lacking methionine and containing 5 g of TUN/ml and then labelled and chased as described for panel A in the presence of the same drug. After the chase, the clarified culture medium (M) and the cell lysates (C) were processed for radioimmunoprecipitation with ␣3 antiserum and SDS-12% PAGE. Positions and sizes of 14 C-radiolabelled marker proteins are on the left. treatment with Endo H. Indeed, unlike its intracellular counterpart, sGP 3 was resistant to digestion by Endo H, suggesting that it had at least reached the medial Golgi compartment. However, digestion with Endo H resulted in a more diffuse pattern of sGP 3 than in the untreated sample ( Fig. 7A ; compare lanes H and U). This result was obtained in two independent experiments and suggests that some carbohydrate side chains may still contain N-linked glycans of the high-mannose or hybrid oligosaccharides. Endo ␤ did not affect sGP 3 , indicating that the smear structure was not due to the presence of poly-N-acetyllactosamine residues. Finally, this released form of GP 3 was not modified by sialic acids or type O glycosylation as judged by the resistance of sGP 3 to treatment by neuraminidase or neuraminidase plus O-glycosidase. The release of sGP 3 from the cell occurs by transit through the secretory pathway. Involvement of the secretory pathway in the transit of the GP 3 subset that is destined to be exported from the cell was first suspected after the demonstration that sGP 3 was essentially Endo H resistant. Thus, to better characterize the sorting process leading to the shedding of a GP 3 fraction in the culture fluids, the influence of protein transport inhibitors such as TUN, BFA, and MNS was studied. TUN is known to prevent modification of proteins by N-linked glycans at very early stages of their synthesis, which may affect their transport. The fungicide BFA inhibits the transport of proteins from the ER to the Golgi apparatus (29, 33, 44) , whereas the monovalent ionophore MNS alters protein translocation through the Golgi network, most likely by blocking the transport at the medial regions of this organelle (15, 46, 48, 53) . Data obtained indicate that inhibition of N-linked glycosylation strongly reduces the rate of sGP 3 release without completely inhibiting this process. Indeed, a small fraction of the nonglycosylated GP 3 (sP3) could be recovered in cells expressing GP 3 in the presence of TUN (Fig. 7B) . A complete inhibition of sGP 3 release was observed in the presence of BFA (Fig. 7B) . It is worth noting that throughout the course of BFA treatment, GP 3 was efficiently synthesized and remained Endo H sensitive (data not shown). MNS at 10 mM was found to interfere with sGP 3 terminal glycosylation but not with its release from the cell. In the presence of this drug, sGP 3 displayed a migration pattern similar to that of the intracellular GP 3 (Fig. 7B ). This released form was Endo H sensitive (data not shown). Taken together, the results indicate that the intracellular itinerary leading to the secretion of a subset of GP 3 involves the vesicular traffic, and that the ER-to-Golgi compartment step is a crucial one for the protein to be released from the cell. Terminal glycosylation of sGP 3 , which results in its diffuse pattern, most likely takes place in a very distal compartment between the medial Golgi and the cell surface. Such a late transport destination appeared not to affect the export of sGP 3 from the cell.
Evidence that sGP 3 folds into a disulfide homodimer. Although the PRRSV GP 3 protein of the IAF-Klop strain of PRRSV was found to diverge significantly from its European homolog (from the LV strain) in terms of amino acid sequence, several cysteine residues are conserved between the two strains (38) . Therefore, the participation of such conserved residues in the establishment of intra-or intermolecular disulfide bonds could be possible. For this purpose, the GP 3 migration pattern from N-ethylmaleimide-treated and [ 35 S]methionine pulse-labelled 293 cells was analyzed under nonreducing conditions. No evidence of the formation of disulfide-linked oligomers of GP 3 was found (data not shown). The only modification was that GP 3 migrated slightly slower than its authentic molecular mass, a finding which could be attributed to the addition of the alkylating agent N-ethylmaleimide. Strikingly, analysis of the released form of GP 3 under nonreducing conditions yielded a predominant protein band of approximately 97 kDa. Given its molecular mass, this protein was considered to be a disulfide-linked homodimer of sGP 3 (Fig. 8) . This result was reproduced in two independent experiments. The small amount of sGP 3 monomers observed under nonreducing con- FIG. 6 . The sGP 3 of the IAF-Klop strain of PRRSV is released from the cell as a membrane-free form. (A) Sensitivity of sGP 3 to trypsin digestion in the presence or absence of detergent. Prior to radioimmunoprecipitation of sGP 3 , the culture medium of 293 cells infected with AdCMV5/ORF3 was supplemented with trypsin, NP-40, and/or trypsin inhibitor as indicated in Materials and Methods. The culture medium was allowed to stand for 30 min at 25°C and was then analyzed by radioimmunoprecipitation. (B) In a second experiment, Triton X-100 was added to the culture medium, which was next subjected to centrifugation at 200,000 ϫ g for 1 to 2 h. The resulting pellet (P) and supernatant (S) fractions were assessed by radioimmunoprecipitation for the presence of sGP 3 .
In both experiments, protein bands between 5 and 30 kDa were not revealed (data not shown). Positions and sizes of 14 C-radiolabelled marker proteins are indicated between the two gels. ditions might have been generated during our experimental procedure. It is important to note that, like sGP 3 , the sGP 3 dimers, which presumably are formed in the ER, could not be detected in cell lysates but were revealed only in the supernatant of 293 cells expressing GP 3 after a lag time similar to that required for the appearance of the monomeric sGP 3 (data not shown). Collectively, these results indicate that GP 3 in its monomeric state was selectively retained in the ER, as demonstrated by its complete and permanent sensitivity to Endo H, whereas the transport-competent fraction, which acquired resistance to Endo H and was released into the culture fluids, appeared to fold into a disulfide-linked dimer.
DISCUSSION
In the present study, the fate of the PRRSV GP 3 It has been demonstrated that the bulk of the GP 3 remained associated with the premedial Golgi compartment, presumably in the ER, as no resistance to Endo H was observed at any time after the protein synthesis. However, the viral protein was shown to be highly glycosylated, suggesting that most of the potential N-linked glycosylation sites were exposed to the lumen of the ER. Although double staining assays were not performed, the fluorescence pattern displayed by GP 3 in 293 cells that have been infected with AdCMV5/ORF3, a recombinant Ad expressing the PRRSV ORF3 gene under the control of the CMV promoter, was quite similar to that observed following incubation of the cells with a rabbit antiserum directed against calnexin (data not shown). Since the latter is an ER resident membrane protein, the data provide strong evidence that PRRSV GP 3 was localized in the ER. Moreover, in comparison to the other PRRSV proteins that are incorporated into virions, GP 3 seems to be rapidly subjected to degradation. This is a characteristic reminiscent of proteins targeted to the ER membrane, presumably because higher concentrations of proteases are found in that subcellular compartment (32, 55) . Data obtained also suggested that the association of GP 3 with the ER does not occur through interactions with other viral products, since no resistance to Endo H could be observed upon individual expression of GP 3 .
The possibility that GP 3 might be intrinsically retained within the ER has led us to examine the primary sequence for the presence of any potential ER-targeting sequence. We have been unable to identify any obvious ER-targeting motifs like the tetrapeptide KDEL-COOH (45), the dilysine ER-targeting signal KKXX-COOH (20, 26) , the consensus sequence YXX LXXR-COOH (34) (where X is any amino acid), or the double arginine motif NH 2 -RR (52) . The absence of a putative ER retention signal correlates with the ability of a GP 3 fraction to be transport competent and finally secreted from the cell. Such a finding raises the question of whether the putative ER retention signal, if one exists, needs to be proteolytically removed in order to allow the protein to be transport competent. Should this be the case, a difference in the molecular mass between the nonglycosylated released fraction and the nonglycosylated ERassociated form would be observed. Data showed that both forms of GP 3 comigrated, and hence, the proteolytic removal of a putative ER targeting sequence may not account for retention of the bulk of GP 3 in the ER. A previous study conducted in vitro with the ORF3 product of LDV allowed its authors to conclude that the protein might be weakly associated with membranes through its uncleaved signal peptide (19) . If we assume that it is also the case for PRRSV GP 3 , then the above finding precludes the possibility that the uncleaved signal sequence may act as an ER retention peptide. In fact, several proteins with uncleaved signal sequences were shown to remain fully transport competent (57) .
Aside from the absence of any recognizable ER retention signal or a putative cleavable membrane anchor sequence, secretion of GP 3 from the cell is in fair agreement with amino acid sequence analysis and in vitro studies with LDV. Indeed, sequence analysis of the ORF3 did not reveal any potential sufficiently hydrophobic domain to act as a membrane anchor sequence. Furthermore, the amino terminus of GP 3 was not found to contain charged residues which might influence the membrane topography of the protein (3). These molecular predictions are similar to those previously reported for the ORF3 product of LDV. The latter was also shown in vitro to be soluble, to associate weakly with membranes, and most probably not to be incorporated into virions (19) . The similarity in the fates of the ORF3 products of both LDV and the Quebec reference strain of PRRSV contrasts with previous findings that LV GP 3 is packaged into virus particles and hence can be described as structural (54) . Most likely, critical residues in the GP 3 primary sequence might determine the difference in its fate.
The fact that only a fraction of PRRSV GP 3 was shown to undergo efficient processing and transport within the secretory pathway leading to its release into the culture medium suggests that this fraction was properly folded in a manner competent for secretion. Thus, the most plausible explanation for the retention of the bulk of GP 3 within the ER might be its inability to undergo efficient folding and its subjection to quality control, a mechanism which prevents misfolded, incorrectly assembled, or unassembled proteins from exiting the ER (for a review, see reference 16). Most often, proteins that do not pass the ER-associated quality control system aggregate, and they are frequently rapidly degraded. The observation that the Endo H-sensitive intracellular pool of GP 3 displayed a relatively rapid turnover is consistent with the above explanation. Another intriguing finding which might be associated with the inability of GP 3 to undergo efficient intracellular transport is that dimerization of the protein was shown to occur only for a small subset of the protein which is transport competent. Thus, it is tempting to speculate that dimerization of GP 3 is a prerequisite for its efficient transport. This observation is not without precedent and was previously documented for several viral proteins. For instance, the ORF2 product of EAV (G s protein) is retained in the ER in its monomeric state, whereas dimers become Endo H resistant and are selectively incorporated into virus particles (13) . Heterotrimer formation between the authentic membrane-integrated G protein of vesicular stomatitis virus and the smaller soluble G s fraction is required for secretion of the latter into the growth medium (51) . By using monomer-and oligomer-specific antibodies to influenza virus hemagglutinin, it was shown that monomers are restricted to the ER, whereas assembled molecules are able to reach distal points in the transport pathway (9) . Furthermore, a fraction of the hemagglutinin of measles virus expressed from a vaccinia virus recombinant was found to be released into the culture medium as a dimer (35) . These are but a few examples emphasizing the importance of the oligomeric assembly in the efficient transport of viral glycoproteins, which may be regarded as a likely explanation for the retention of the PRRSV GP 3 in the ER. In this respect, it would be of interest to look for a possible association of GP 3 with molecular chaperones such as immunoglobulin heavy-chain-binding protein and calnexin, which are known to bind to improperly assembled proteins trapped as large covalent or noncovalent aggregates in the ER (2, 31, 47) . Data also indicate that only a very small fraction of GP 3 was able to exit the ER and transit through the secretory pathway to its final destination, the extracellular medium. This conclusion stems from the following observations: (i) sGP 3 could not be precipitated from the cell lysates, (ii) it appears in the culture medium after a lag time of at least 1 h, and (iii) the amount of this extracellular secreted form increased as a function of time. As mentioned above, these features of sGP 3 also characterize the dimeric form of sGP 3 . It is actually unclear why only a small fraction of GP 3 became transport competent. Is it for functional purposes that the bulk of GP 3 was restricted to the ER? Or is it a regulation mechanism that allowed the secretion of only a small fraction of GP 3 that is sufficient to fulfill a yet-unidentified role? In fact, secretion of a subset of GP 3 in the culture medium contrasts with the tendency of PRRSV to localize and assemble its glycoproteins in intracytoplasmic membranes, where budding appears to occur (50) . The propensity of PRRSV glycoproteins to localize to the premedial Golgi compartment now becomes more evident (37, 40, 43) . Indeed, unlike GP 3 , the GP 2 , GP 4 , and GP 5 proteins displayed a very slow processing of their carbohydrate moieties to the complex type. Thus, as with some coronaviruses, bunyaviruses, and hepadnaviruses (4, 5, 7, 56) , intracytoplasmic assembly and budding of PRRSV might be viewed as a strategy to evade host immune detection and hence, secretion of a subset of GP 3 would not be in line with such a mechanism. At present, the release of sGP 3 may explain why the proteins, though nonstructural, elicits a strong antibody response in infected animals, at least in the case of the North American IAF-Klop strain (22) . Such a finding was also reported for the GP 3 counterpart in LDV (19) . The role of anti-GP 3 antibodies in the evolution of the PRRSV and LDV infections remains to be defined.
The coding sequence of GP 3 is the most variable among PRRSV strains (17, 38) , the major amino acid variations being at the amino terminus. Since this region carries signals that influence the destiny of most proteins, it is conceivable that the difference in the fate of GP 3 in North American and European strains may lie in this portion of the protein. Further studies involving the construction of GP 3 chimeras and the generation of mutants may certainly help us to learn more about the biogenesis and the role of this protein. However, one can speculate that since GP 3 is not packaged in the case of the North American IAF-Klop PRRSV strain, this protein may not be necessary for the initiation of the virus infection.
